The most widely investigated c-KIT inhibitor was imatinib, which served as the first-line drug in GIST (Blay et al., 2015), whereas as an alternative treatment beyond immunotherapy in melanoma (Carvajal et al., 2011; Guo et al., 2011; Delyon et al., 2020). Here, KIT is linked to melanoma.